AI Article Synopsis

  • Cholangiocarcinoma is a deadly cancer that affects the bile ducts and is often diagnosed too late for surgery, making early detection crucial.
  • Surgical removal of the tumor is the best chance for long-term survival, but most patients are not candidates due to the late stage of the disease.
  • The article discusses current treatment strategies, focusing on new biomarkers for early diagnosis and alternative therapies for those who can’t undergo surgery.

Article Abstract

Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.34541DOI Listing

Publication Analysis

Top Keywords

patients unresectable
8
early detection
8
novel biomarkers
8
multidisciplinary management
4
management cholangiocarcinoma
4
cholangiocarcinoma cholangiocarcinoma
4
cholangiocarcinoma lethal
4
lethal malignancy
4
malignancy biliary
4
biliary epithelium
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!